ARTICLE SUMMARY:
The CPT coding process, managed by the American Medical Association, has long been seen by industry and others as a black box with little insight shared on how this critical part of the reimbursement process actually works. That may be changing as reflected by this rare look inside the system from one of the organization’s senior leaders. Part 1 of a 2-part interview.
Ten years ago, if you would have asked US medtech executives and their investors to identify the primary issue facing their companies (along with the perennial problem of financing), the clear winner would have been regulatory obstacles. But in the last decade, things have changed dramatically at the FDA, with the agency adapting to work more closely with industry and implementing new processes to speed innovation and help companies bring products to market more quickly.
